Kenvue Inc. Q3 FY25 Results — Earnings Call Analysis

Published 29 May 2026 | Personal Care Products | Market Cap: ₹33.9K Cr

- Guidance for 2025 expects low single-digit declines in organic sales for the full year, with potential to be at the top of that range if innovations and other factors are incremental (Page 12). - Full-year organic sales guidance is a low single-digit decline, reflecting a soft category environment and cautious consumer sentiment (Page 12).

From Kenvue Inc.'s Q3 FY25 earnings-call transcript · updated 29 May 2026.

Price

₹17.64

Market Cap

₹33.9K Cr

P/E Ratio

20.8

Revenue Rank

Rank 5

Margin Rank

Rank 5

How does Kenvue Inc. rank in Personal Care Products?

Compare Kenvue Inc. against every Personal Care Products company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 5Margin: Rank 5

View Personal Care Products leaderboard →

📊 Revenue & Sales Performance

Rank 5

→Guidance for 2025 expects low single-digit declines in organic sales for the full year, with potential to be at the top of that range if innovations and other factors are incremental (Page 12).
→The first half closed at around a 2.7% decline; category softness and cautious consumer sentiment are factored into guidance (Page 12).
→Innovation in the second half and lapping trade accruals and China weakness in Q4 may improve results (Page 12).
→Global consumption stabilized for the first time since Q3 2023, but organic sales continue to lag (Page 6).
→Some brands like Tylenol and Nicorette show strong growth and share gains, indicating pockets of growth (Pages 6, 7, and 9).
→Overall, the expectation is cautious with a focus on innovation, brand execution, and reduced complexity to drive sustainable growth (Pages 9, 11, 12).

📈 Profitability & Margins

Rank 5

→Full-year organic sales guidance is a low single-digit decline, reflecting a soft category environment and cautious consumer sentiment (Page 12).
→EPS guidance range is $1 to $1.05, including a low single-digit drag from currency (Page 7).
→Adjusted operating margin is expected to contract versus last year due to strategic price investments, fixed cost deleverage, inflationary pressures, and tariffs (~$150 million gross impact), which are only partially offset by productivity initiatives (Page 7).
→Urgent actions are underway to curtail discretionary spend and accelerate productivity for margin improvement (Pages 7, 12).
→Despite earnings headwinds, cash flow is expected to remain in the same neighborhood as last year, driven by working capital and supply chain improvements (Page 11).
→Innovation and brand investments will be more focused and choiceful to drive higher ROI and sustainable growth (Page 7).
→A strategic review is ongoing, which may influence future growth and margin trajectories (Pages 10, 11).

🏗️ Capital Expenditure Plans

No information

→The company is undertaking urgent actions to curtail discretionary spend and accelerate productivity measures.
→They plan to continue supporting brands at a higher level than last year but will be more choiceful, redirecting spending towards higher ROI initiatives.
→Work is underway to optimize brand investment spend for higher ROI.
→Modernizing and optimizing systems, processes, and technologies is a key enabler to drive digital and data strategies, productivity, and efficiency.
→The supply chain transformation is expected to deliver benefits across inventory and payables, improving cash flow conversion.
→No specific dollar amounts or detailed future capital expenditure plans were disclosed, but investments are focused on modernization, innovation, and operational improvements.

💰 Fundraising & Capital Structure

No information

Based on the provided transcript from pages 3 to 12 of the document "2058284-2974.pdf," there is no explicit mention or indication of any current or planned new fundraising activities through debt or equity. Key points include: - The company is focused on improving operational performance and executing a strategic review. - Discussions address improving growth, reducing complexity, and optimizing spending but do not mention raising capital. - There is mention of driving efficiencies, cost savings, and improving cash flow conversion. - No direct references to issuing new debt or equity or plans for fundraising. - The Board is considering strategic alternatives but no details about capital raising are disclosed. Therefore, no current or future fundraising via debt or equity is communicated in these sections.

📋 Order Book & Pipeline

The provided pages do not mention specific details about the current or expected order book or pending orders. The discussion primarily covers: - Sales guidance: Expecting low single-digit declines for the full year, including what was seen in the first half. - Category softness: Categories have softened with cautious consumer sentiment factored into guidance. - Inventory dynamics: Retail inventory destocking and trade accrual lapsing affecting sales, especially in China and the U.S. - Operational focus: Emphasis on innovation, execution, and category management to drive sales improvements. - No explicit data or commentary on order books or pending orders is provided in these pages.

Key Metrics

Revenue

Rank 5

Margin

Rank 5

Capex

No information

Fundraise

No information

Order Book

Frequently Asked Questions

What were Kenvue Inc. Q3 FY25 results?

What is Kenvue Inc. share price analysis?

Kenvue Inc. currently shows a neutral. The stock trades at a P/E of 20.8 with a market cap of $33,869. Investors should review the full earnings analysis for detailed insights.

Is Kenvue Inc. planning capital expenditure?

- The company is undertaking urgent actions to curtail discretionary spend and accelerate productivity measures.

Keep Kenvue Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.